Alpha Cognition (ACOG) vs PepGen (PEPG)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Alpha Cognition (ACOG) has outperformed PepGen (PEPG) over the past year, gaining 19.4% versus a loss of 47.9%. Alpha Cognition is the larger company by market cap ($196.9 million vs $181.2 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ACOG | PEPG |
|---|---|---|
| Share price | $9.04 | $2.62 |
| Market cap | $196.87M | $181.22M |
| 1-day change | 0.00% | +10.08% |
| YTD return | +39.08% | -59.75% |
| 1-year return | +19.42% | -47.91% |
| EPS (TTM) | $-1.32 | $-1.01 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $10.14 | $7.80 |
| 52-week low | $4.50 | $1.31 |
| Distance from 52-week high | -10.85% | -66.41% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +99.12% | +288.93% |
| Average volume | 125.72K | 923.99K |
| Shares outstanding | 21.78M | 69.17M |
| Employees | 71 | 57 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ACOG has outperformed PEPG by 67.3 percentage points over the past year.
About Alpha Cognition
ACOG stock →Alpha Cognition Inc., a biopharmaceutical company, engages in the development of treatments for patients suffering from neurodegenerative diseases in the United States and Canada. The company's commercial development program includes ZUNVEYL oral tablet formulation for treating Alzheimer's disease.
Healthcare · Biotechnology · 71 employees
About PepGen
PEPG stock →PepGen Inc., a clinical-stage biotechnology company, develops oligonucleotide therapeutics for the treatment of severe neuromuscular and neurologic diseases in the United States. The company engages in the development of PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 2 clinical trial for the treatment of myotonic dystrophy type 1; and FREEDOM2-DM1, which is in Phase 2 for the treatment of myotonic dystrophy type 1.
Healthcare · Biotechnology · 57 employees
ACOG vs PEPG FAQ
Which is bigger, Alpha Cognition or PepGen?
Alpha Cognition (ACOG) is larger, with a market capitalization of $196.87M compared with $181.22M for PepGen (PEPG).
Which stock has performed better over the past year, ACOG or PEPG?
ACOG returned +19.42% over the past 12 months, compared with -47.91% for PEPG (price return, excluding dividends). Past performance does not predict future results.
Are Alpha Cognition and PepGen in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.